News summary
[Hengrui Pharmaceutical: Will acquire a 19.9% stake in Hercules Inc.] Securities Times e Company NewskalajackpotHengrui Pharmaceutical (600276) announced on the evening of May 16 that the company will license the GLP-1 product portfolio with independent intellectual property rights to HerculesCMNewco for a paid feekalajackpot,Inc. (abbreviated as "American Herc...
Newsletter text
[Hengrui Pharmaceutical: Will acquire a 19.9% stake in Hercules, Inc.] Securities Times e Company News, Hengrui Pharmaceutical (600276) announced on the evening of May 16 that the company will license its GLP-1 product portfolio with independent intellectual property rights to HerculesCMNewco,Inc. (referred to as "Hercules USA"), Hercules USA will receive exclusive rights to develop, produce and commercialize the GLP-1 product portfolio on a global scale except Greater China. As part of the consideration for the external licensing transaction, Hengrui will obtain a 19.9% equity interest in Hercules, Inc., and will receive a GLP-1 product portfolio licensing fee from Hercules, Inc., Inc. The GLP-1 product portfolio is an innovative drug independently developed by Hengrui for diabetes, obesity and other metabolic diseases.
